Buy Retatrutide Online — 4 sizes (10 mg–30 mg)
Incretin pathway research — built around cross-species metabolic comparisons.
Retatrutide is a triple agonist targeting the GLP-1, GIP, and glucagon receptors — the broadest incretin/counterregulatory activation profile studied in peptide research to date. It is frequently benchmarked in the literature against dual agonists like tirzepatide and pure GLP-1 agonists like semaglutide.
Vial sizes and price per mg
Up to 27% cheaper per mgReconstitution volumes
Volumes of bacteriostatic water required to dissolve each vial at common research concentrations.
| Vial | at 2 mg/mL | at 5 mg/mL | at 10 mg/mL |
|---|---|---|---|
| 10 mg | 5 mL | 2 mL | 1 mL |
| 15 mg | 7.50 mL | 3 mL | 1.50 mL |
| 20 mg | 10 mL | 4 mL | 2 mL |
| 30 mg | 15 mL | 6 mL | 3 mL |
Numbers are calculated from the stated vial mass. Verify against the supplier's instructions for your specific research protocol.
Mechanism in the literature
By recruiting glucagon-receptor signaling alongside the two incretin receptors, retatrutide is proposed to add an energy-expenditure component on top of the appetite-suppression and insulinotropic effects typical of GLP-1/GIP activation. This triple-agonist design is the current frontier of peptide metabolic research.
Research use-cases
- Triple agonist: GLP-1 + GIP + glucagon receptor
- Available in 10, 15, 20, and 30 mg research vials
- Among the most-discussed new research compounds in metabolic studies
- Studied head-to-head with tirzepatide in comparative protocols
Often paired with
Buyers viewing Retatrutide typically also consider 5-Amino-1MQ, Adipotide (FTPP) and SLU-PP-332 Capsules. Each is in stock, sealed under nitrogen with a lot-matched CoA.
Handling in the lab
Weekly-dosing protocols dominate the research literature. Reconstitution in BAC water with careful aliquoting is standard. Lower starting concentrations are typical during titration phases.
Stacking and paired-compound work
Reta-Cagri (retatrutide + cagrilintide) blends appear in comparative amylin-co-agonism research. Retatrutide is rarely stacked with other GLP-1 compounds.
Frequently asked
Why is retatrutide called a "triple agonist"?
It activates three distinct receptors — GLP-1, GIP, and glucagon — rather than one (semaglutide) or two (tirzepatide).
Is retatrutide more potent than tirzepatide in research models?
Published comparisons report stronger endpoints in some metabolic models, though the full picture is still being characterized in ongoing studies.
What is the typical half-life in research?
Weekly dosing schedules are standard, consistent with a multi-day pharmacokinetic profile.
How should multiple vial sizes be chosen?
Match total study duration × weekly concentration to choose the most cost-efficient vial size.
More Fat Loss compounds
-10%
5 sizes-10%
2 sizes-10%
-10%